Literature DB >> 18029939

Resistant gram-negative bacilli: A neglected healthcare crisis?

Ebbing Lautenbach1, Ron E Polk.   

Abstract

PURPOSE: Infections caused by drug-resistant gram-negative bacteria are a growing threat to the healthcare community and clinicians are encouraged to employ a combination of strategies for effective prevention and treatment of these difficult infections.
SUMMARY: Recent epidemiological studies suggest an increase in healthcare- associated infections caused by gram-negative bacteria, particularly Klebsiella spp., Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter spp. The rising incidence of drug resistance of these pathogens presents a challenge given the few novel antimicrobial agents under development that specifically target these organisms. To combat this trend, recent guidelines promote Antimicrobial Stewardship Programs (ASP) as an effective means to possibly control the emergence and spread of antimicrobial resistance. Two key ASPs strategies include prospective audit, intervention, and feedback, and formulary restriction and preauthorization. The best methods to measure antimicrobial use and antimicrobial resistance are still being developed. In addition, using pharmacokinetics and pharmacodynamics priniciples to guide antimicrobial dosing regimens may have a role in controlling development of resistance. Finally, enforcing rigorous infection control practices can reduce the transmission of problematic pathogens within the healthcare setting.
CONCLUSION: With a limited number of antimicrobial agents in development, clinicians cannot rely on new drugs alone to treat infections due to drug-resistant gram-negative bacteria but must also incorporate strategies that reduce the emergence of resistance and prevent the spread of problematic bacteria. Potentially effective interventions include antimicrobial stewardship tactics that advocate optimal use of currently available antimicrobial agents and rigorous infection control measures. Infectious diseases trained pharmacists are in a unique position to play a key role in helping control the spread of nosocomial pathogens.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18029939     DOI: 10.2146/ajhp070477

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  18 in total

1.  In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae.

Authors:  Dora E Wiskirchen; Jared L Crandon; Guilherme H Furtado; Gregory Williams; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-04-25       Impact factor: 5.191

2.  A clinical prediction rule for fluoroquinolone resistance in healthcare-acquired gram-negative urinary tract infection.

Authors:  Pinyo Rattanaumpawan; Pam Tolomeo; Warren B Bilker; Ebbing Lautenbach
Journal:  Infect Control Hosp Epidemiol       Date:  2011-09-29       Impact factor: 3.254

3.  Epidemiology of infections due to extended-spectrum Beta-lactamase-producing bacteria in a pediatric intensive care unit.

Authors:  Kim W Benner; Priya Prabhakaran; Autumn S Lowros
Journal:  J Pediatr Pharmacol Ther       Date:  2014-04

Review 4.  Hospital epidemiology and infection control in acute-care settings.

Authors:  Emily R M Sydnor; Trish M Perl
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

5.  Attributable Cost and Length of Stay Associated with Nosocomial Gram-Negative Bacterial Cultures.

Authors:  Richard E Nelson; Vanessa W Stevens; Makoto Jones; Karim Khader; Marin L Schweizer; Eli N Perencevich; Michael A Rubin; Matthew H Samore
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

6.  Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women.

Authors:  Kevin P Connors; Seth T Housman; J Samuel Pope; John Russomanno; Edward Salerno; Eric Shore; Susan Redican; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

7.  In vitro activities of sitafloxacin tested alone and in combination with rifampin, colistin, sulbactam, and tigecycline against extensively drug-resistant Acinetobacter baumannii.

Authors:  Xiaomeng Dong; Fengzhe Chen; Yajun Zhang; Haihong Liu; Yongjuan Liu; Lixian Ma
Journal:  Int J Clin Exp Med       Date:  2015-05-15

8.  Risk factors and outcomes of infections caused by extremely drug-resistant gram-negative bacilli in patients hospitalized in intensive care units.

Authors:  Sameer J Patel; André P Oliveira; Juyan Julia Zhou; Luis Alba; E Yoko Furuya; Scott A Weisenberg; Haomiao Jia; Sarah A Clock; Christine J Kubin; Stephen G Jenkins; Audrey N Schuetz; Maryam Behta; Phyllis Della-Latta; Susan Whittier; Kyu Rhee; Lisa Saiman
Journal:  Am J Infect Control       Date:  2014-04-13       Impact factor: 2.918

9.  Chloramphenicol - A Potent Armament Against Multi-Drug Resistant (MDR) Gram Negative Bacilli?

Authors:  Smita Sood
Journal:  J Clin Diagn Res       Date:  2016-02-01

10.  In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.

Authors:  Shawn H MacVane; Jared L Crandon; Wright W Nichols; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.